Phenotypes and genetic mechanisms of resistance to macrolides and lincosamides in viridans group streptococci;Fenotipos y mecanismos genéticos de resistencia a macrólidos y lincosamidas en estreptococos del grupo viridans

Revista Espanola de Quimioterapia

Volumn 20, Issue 3, 2007, Pages 317-322

  Artiles Campelo, Fernando ^a   Horcajada Herrera, I ^a   Alamo Antunez I ^a   Canas Pedrosa A ^a   Lafarga Capuz, B ^a  

^a HOSPITAL UNIVERSITARIO DE GRAN CANARIA DR NEGRÍN   (Spain)

Author keywords

Co resistance; Genetic mechanism; Macrolide resistance; Phenotype; Viridans group streptococci

Indexed keywords

CEFOTAXIME; CLINDAMYCIN; ERYTHROMYCIN; GENTAMICIN; LINCOSAMIDE DERIVATIVE; MACROLIDE; PENICILLIN G;

ABDOMINAL ABSCESS; AGAR GEL DIFFUSION; ALPHA HEMOLYTIC STREPTOCOCCUS; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM IDENTIFICATION; BACTERIUM ISOLATE; BLOOD CULTURE; DRUG EFFICACY; NONHUMAN; PHENOTYPE; POLYMERASE CHAIN REACTION; STREPTOCOCCUS ANGINOSUS;

ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; DNA, BACTERIAL; DRUG RESISTANCE, MULTIPLE, BACTERIAL; GENES, BACTERIAL; HUMANS; MACROLIDES; MEMBRANE PROTEINS; METHYLTRANSFERASES; MICROBIAL SENSITIVITY TESTS; PHENOTYPE; POLYMERASE CHAIN REACTION; STREPTOCOCCAL INFECTIONS; VIRIDANS STREPTOCOCCI;

EID: 36949012294     PISSN: 02143429     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Prabhu, R.M., Piper, K.E., Baddour, L.M. y cols. Antimicrobial susceptibility patterns among viridans group streptococcal isolates from infective endocarditis patients from 1971 to 1986 and 1994 to 2002. Antimicrob Agents Chemother 2004; 48: 4463-4465.
2. Wisplinghoff, H., Reinert, R.R., Cornely, O., Seifert, H. Molecular relationships and antimicrobial susceptibilities of viridans group streptococci isolated from blood of neutropenic cancer patients. J Clin Microbiol 1999; 37: 1876-1880.
3. Bayer, A.S., Scheid, W.M. Endocarditis and intravascular infections. En: Mandell, G.L., Bennett, J.E., Dolin, R. (Eds.). Principles and practice of infectious diseases. Churchill Livingstone, Inc., New York 2000; 857-884.
4. Aracil, B., Gómez-Garcés, J.L., Alós, J.I. A study of susceptibility of 100 clinical isolates belonging to the Streptococcus milleri group to 16 cephalosporins. J Antimicrob Chemother 1999; 43: 399-402.
5. Rodríguez-Avial, C., Rodríguez-Avial, I., Picazo, J.J. Estreptococos del grupo viridans: Resistencia antimicrobiana e impacto clínico. En: Bouza, E., Picazo, J.J. (Eds.). Infección. Servisistem 2000, Bilbao 2003; 145-176.
6. Razonable, R.R., Litzow, M.R., Khaliq, Y. y cols. Bacteremia due to viridans group streptococci with diminished susceptibility to levofloxacin among neutropenic patients receiving levofloxacin prophylaxis. Clin Infect Dis 2002; 34: 1469-1474.
7. Farrell, D.J., Morrissey, I., Bakker, S., Buckridge, S., Felmingham, D. In vitro activities of telithromycin, linezolid, and quinupristin- dalfopristin against Streptococcus pneumoniae with macrolide resistance due to ribosomal mutations. Antimicrob Agents Chemother 2004; 48: 3169-3171.
8. Ruoff, K.L., Whiley, R.A., Beighton, D. Streptococcus. En: Murray, P.R., Baron, E.J., Jorgensen, J.H., Pfaller, M.A., Yolken, R.H. (Eds.). Manual of clinical microbiology. ASM Press, Washington, D.C., 2003; 405-421.
9. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing, 16th informational supplement. CLSI Document M100-S16. CLSI, Wayne, Pennsylvania, 2006.
10. Farrell, D.J., Morrissey, I., Bakker, S., Felmingham, D. Molecular characterization of macrolide resistance mechanisms among Streptococcus pneumoniae and Streptococcus pyogenes isolated from the PROTEKT 1999-2000 study. J Antimicrob Chemother 2002; 50 (Suppl. S1): 39-47.
11. Sutcliffe, J., Grebe, T., Tait-Kamradt, A., Wondrack, L. Detection of erythromycin-resistant determinants by PCR. Antimicrob Agents Chemother 1996; 44: 2562-2566.
12. Amezaga, M.R., Carter, P.E., Cash, P., McKenzie, H. Molecular epidemiology of erythromycin resistance in Streptococcus pneumoniae isolates from blood and noninvasive sites. J Clin Microbiol 2002; 40: 3313-3318.
13. Tait-Kamradt, A., Davies, T., Cronan, M. y cols. Mutations in 23S rRNA and ribosomal protein L4 account for resistance in pneumococcal strains selected in vitro by macrolide passage. Antimicrob Agents Chemother 2000; 44: 2118-2125.
14. Cerdá-Zolezzi, P., Millán-Laplana, L., Rubio-Calvo, C. y cols. Molecular basis of resistance to macrolides and other antibiotics in commensal viridans group streptococci and Gemella spp. and transfer of resistance genes to Streptococcus pneumoniae. Antimicrob Agents Chemother 2004; 48: 3462-3467.
15. Aracil, B., Miñambres, M., Oteo, J. y cols. High prevalence of erythromycin-resistant and clindamycin-susceptible (M phenotype) viridans group streptococci from pharyngeal samples: A reservoir of mef genes in commensal bacteria. J Antimicrob Chemother 2001; 48: 587-595.
16. Seppälä, H., Haanperä, M., Al-Juhaish, M. y cols. Antimicrobial susceptibility patterns and macrolide resistance genes of viridans group streptococci from normal flora. J Antimicrob Chemother 2003; 52: 636-644.
17. Pérez-Trallero, E., Vicente, D., Montes, M., Marimón, J.M., Piñeiro, L. High proportion of pharyngeal carriers of commensal streptococci resistant to erythromycin in Spanish adults. J Antimicrob Chemother 2001; 48: 225-229.
18. Jacobs, J.A., Van Baar, G.J., London, N.H. y cols. Prevalence of macrolide resistance genes in clinical isolates of the Streptococcus anginosus ("S. milleri") group. Antimicrob Agents Chemother 2001; 45: 2375-2377.
19. Clarridge III, J.E., Attorri, S., Musher, D.M., Hebert, J., Dunbar, S. Streptococcus intermedius, Streptococcus constellatus, and Streptococcus anginosus ("Streptococcus milleri group") are of different clinical importance and are not equally associated with abscess. Clin Infect Dis 2001; 32: 1511-1515.
20. Facklam, R. What happened to the Streptococci: Overview of taxonomic and nomenclature changes. Clin Microbiol Rev 2002; 15: 613-630.